Or Yat Sun 4
4 · ENANTA PHARMACEUTICALS INC · Filed Mar 17, 2023
Insider Transaction Report
Form 4
Or Yat Sun
Chief Scientific Officer
Transactions
- Sale
Common Stock
2023-03-15$43.92/sh−269$11,814→ 388,358 total - Exercise/Conversion
Common Stock
2023-03-15$14.00/sh+13,925$194,950→ 388,627 total - Sale
Common Stock
2023-03-15$44.46/sh−13,656$607,146→ 374,702 total - Exercise/Conversion
Stock Option (Right to Buy)
2023-03-15−13,925→ 0 totalExercise: $14.00Exp: 2023-03-21→ Common Stock (13,925 underlying)
Footnotes (4)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in November 2022.
- [F2]The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $43.86 to $43.96, inclusive.
- [F3]The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $44.02 to $45.00, inclusive.
- [F4]On March 21, 2013, the reporting person was granted an option to purchase 41,763 shares of common stock, half of which became exercisable upon the achievement of several clinical milestones during the four-year performance period after the date of grant.